Table 3

Primary endpoint, impact of the time of initiation of antibiotic therapy on neonatal outcome

Adjusted OR (95% CI)P valueHosmer and Lemeshow goodness-of-fit testNagelkerke R2
Outcome BPD
Time of initiation of ABT0.120.30
 No ABT1
 ABT start, day 1 or 2 3.06 (1.36 to 6.88) 0.01
 ABT start, days 3–6 2.79 (1.11 to 7.00) 0.03
 ABT start, day ≥71.31 (0.39 to 4.37)0.66
Outcome IVH
Time of initiation of ABT0.740.21
 No ABT1
 ABT start, day 1 or 2 2.13 (1.07 to 4.25) 0.03
 ABT start day, days 3–61.41 (0.57 to 3.48)0.46
 ABT start, day ≥7 3.07 (1.22 to 7.73) 0.02
Outcome death
Time of initiation of ABT0.250.25
 No ABT1
 ABT start, day 1 or 2 2.54 (1.31 to 4.97) 0.01
 ABT start, days 3–61.72 (0.71 to 4.16)0.23
 ABT start, day ≥7 3.13 (1.24 to 7.88) 0.02
  • BPD: model adjusted by GA, antenatal steroids, base excess, SGA, Apgar score at 5 min, central line, tracheal ventilation, sepsis and NEC.

  • IVH: model adjusted by GA, antenatal steroids, Apgar score at 10 min, mode of birth, IAI, arterial line, tracheal ventilation and FIP surgery.

  • IVH: model adjusted by GA, antenatal steroids, Apgar score at 10 min, mode of birth, IAI, arterial line, tracheal ventilation and FIP surgery.

  • Bold type: significant adjusted OR are shown in bold.

  • ABT, antibiotic therapy; BPD, bronchopulmonary dysplasia; FIP, focal intestinal perforation; GA, gestational age; IAI, intra-amniotic infection; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; SGA, small for gestational age.